Veerle Bossuyt, Rosanna Lau, Brandon Young, John Greg Howe, Fengmin Zhao, Brian Leyland-Jones, Lili Du, Tiffany Foli, Christos Hatzis, W Fraser Symmans
BACKGROUND: The sensitivity to endocrine therapy assay (SET2,3) predicts treatment outcomes in Stage II-III breast cancer. SET2,3 measures transcription related to estrogen and progesterone receptors (SETER/PR index) and the molecular subtype (RNA4: ESR1, PGR, ERBB2, AURKA) from formalin-fixed paraffin-embedded (FFPE) tissue sections. METHODS: We designed a nested study across 3 pathology laboratories, each testing 60 breast cancers twice in controlled batches. Laboratories macrodissected and directly homogenized the unstained FFPE tumor sections, then performed the QuantiGene Plex bead-based hybridization assay...
September 1, 2021: Clinical Chemistry